Curis to Showcase at the 30th Annual SNO Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Should l Buy CRIS?
Source: Newsfilter
Curis, Inc. Announcement: Curis, Inc. will present clinical and preclinical data on emavusertib, an IRAK4 inhibitor, at the 30th Annual Meeting of the Society for Neuro-Oncology from November 19-23, 2025.
Presentation Details: Key presentations include analyses of genetic mutation profiles and CNS pharmacokinetics in relapsed/refractory primary CNS lymphoma patients, as well as preliminary safety and efficacy results of emavusertib in combination with ibrutinib.
Ongoing Studies: Emavusertib is being evaluated in multiple studies, including its use in combination therapies for relapsed/refractory primary CNS lymphoma, acute myeloid leukemia, and high-risk myelodysplastic syndrome.
Regulatory Designations: Emavusertib has received Orphan Drug Designation from the FDA and the European Commission for the treatment of primary CNS lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRIS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRIS
Wall Street analysts forecast CRIS stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.080
Low
5.00
Averages
11.00
High
17.00
Current: 1.080
Low
5.00
Averages
11.00
High
17.00
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Curis Closes $80.8 Million PIPE Financing to Advance Emavusertib Development
- Successful Financing: Curis, Inc. has successfully closed a PIPE financing round, securing up to $80.8 million in gross proceeds, including approximately $20.2 million in initial proceeds, which will provide crucial funding for the development of its drug emavusertib, supporting the company's ongoing growth in the biotechnology sector.
- Investor Participation: The financing attracted participation from several healthcare-focused institutional investors, including Nantahala Capital and Stonepine Capital Management, reflecting strong market confidence in Curis and its development pipeline, thereby enhancing the company's capital foundation.
- Drug Development Progress: Emavusertib, a small molecule IRAK4 and FLT3 inhibitor, is currently undergoing clinical trials for relapsed/refractory primary central nervous system lymphoma and has received Orphan Drug Designation from the FDA, indicating its potential market value in the treatment landscape.
- Future Development Plans: Curis plans to continue advancing emavusertib in both monotherapy and combination treatments for acute myeloid leukemia, and with this financing, the company expects to accelerate its clinical development process, enhancing its competitiveness in the biopharmaceutical industry.
See More
Curis Closes $80.8 Million PIPE Financing to Advance Cancer Drug Development
- Successful Financing: Curis, Inc. has closed a PIPE financing of up to $80.8 million, with initial gross proceeds of approximately $20.2 million, significantly enhancing the company's financial capacity to advance the development of its cancer drug emavusertib.
- Investor Participation: The financing attracted participation from several healthcare-focused institutional investors, including Nantahala Capital and Stonepine Capital Management, reflecting strong market confidence in Curis's future growth prospects.
- Drug Development Progress: Emavusertib is currently undergoing clinical trials for relapsed/refractory primary central nervous system lymphoma, which is expected to provide new treatment options for patients and further solidify the company's position in the biotechnology sector.
- Strategic Collaboration: Curis's collaboration with Aurigene Discovery Technologies grants it exclusive rights to develop emavusertib, with plans to continue clinical research in areas such as acute myeloid leukemia, thereby expanding its therapeutic portfolio.
See More
Innovative Eyewear Inc Reports 45% Year-over-Year Sales Growth in Q4
- Significant Sales Growth: Innovative Eyewear Inc (LUCY) reported preliminary Q4 sales of approximately $1 million, reflecting a 45% year-over-year increase, indicating enhanced competitiveness in the market that may attract more investor interest.
- Stock Surge: Following the sales report, LUCY's stock price surged 47% to $1.74, reflecting strong market confidence in the company's future growth potential, which could further enhance its financing capabilities.
- Industry Dynamics: The ISM services PMI rose for the third consecutive month to a reading of 54.4 in December, exceeding market expectations of 52.3, indicating signs of economic recovery that may positively influence overall market sentiment.
- Labor Market Changes: U.S. job openings fell by 303,000 to 7.146 million in November, marking the lowest level since December 2020, suggesting potential pressures in the labor market that could impact future economic growth expectations.
See More
UniFirst Corp Reports Mixed Q1 Results, Shares Drop 4%
- Earnings Miss: UniFirst Corp reported adjusted earnings of $1.97 per share for Q1, falling short of market expectations of $2.06, indicating challenges in profitability that may affect investor confidence.
- Sales Slightly Exceed Expectations: The company’s quarterly sales reached $621.318 million, slightly above the expected $615.253 million, suggesting some market demand remains despite earnings concerns.
- Stock Price Reaction: Following the mixed results, UniFirst's shares dropped approximately 4% on Wednesday, reflecting market worries about the company's future profitability and potentially prompting investors to reassess their strategies.
- Industry Impact: In a mixed market where healthcare stocks rose by 1.4% and materials stocks fell by 1%, UniFirst's performance may influence its competitive position within the materials sector.
See More
Curis Secures $80.8 Million PIPE Financing to Support R&D Efforts
- Financing Size: Curis, Inc. has entered into a securities purchase agreement for a PIPE financing of up to $80.8 million, with initial gross proceeds of approximately $20.2 million expected to close on January 8, 2026, significantly enhancing the company's liquidity to support R&D.
- Equity Structure: The financing includes 20,195 shares of Series B convertible preferred stock and various warrants, which are expected to provide additional capital to advance the company's drug development in acute myeloid leukemia and other cancers.
- Strategic Use: Curis intends to utilize the initial net proceeds for research and development, general corporate expenses, and working capital needs, ensuring the company maintains a competitive edge in the biotechnology sector.
- Market Reaction: The successful completion of this financing is expected to accelerate the clinical trial process for emavusertib, enhancing market confidence in its products, which could positively impact the company's future stock price.
See More
Curis Secures $80.8 Million in PIPE Financing
- Financing Size: Curis, Inc. announced a securities purchase agreement for a PIPE financing expected to yield up to $80.8 million, with initial gross proceeds of approximately $20.2 million, highlighting the company's appeal in the biotechnology sector.
- Investor Composition: The financing attracted several high-quality healthcare institutional investors and company insiders, indicating strong market confidence and support for Curis, which may enhance the company's funding strength for future R&D.
- Use of Funds: Curis intends to utilize the initial net proceeds for research and development, general corporate expenses, and working capital needs, ensuring its sustained growth in the competitive biopharmaceutical market.
- Shareholder Approval: The issuance of Series B Preferred Stock and Warrants requires shareholder approval, and the successful completion of this process will lay the groundwork for optimizing the company's future capital structure.
See More
Curis Closes $80.8 Million PIPE Financing to Advance Emavusertib Development
- Successful Financing: Curis, Inc. has successfully closed a PIPE financing round, securing up to $80.8 million in gross proceeds, including approximately $20.2 million in initial proceeds, which will provide crucial funding for the development of its drug emavusertib, supporting the company's ongoing growth in the biotechnology sector.
- Investor Participation: The financing attracted participation from several healthcare-focused institutional investors, including Nantahala Capital and Stonepine Capital Management, reflecting strong market confidence in Curis and its development pipeline, thereby enhancing the company's capital foundation.
- Drug Development Progress: Emavusertib, a small molecule IRAK4 and FLT3 inhibitor, is currently undergoing clinical trials for relapsed/refractory primary central nervous system lymphoma and has received Orphan Drug Designation from the FDA, indicating its potential market value in the treatment landscape.
- Future Development Plans: Curis plans to continue advancing emavusertib in both monotherapy and combination treatments for acute myeloid leukemia, and with this financing, the company expects to accelerate its clinical development process, enhancing its competitiveness in the biopharmaceutical industry.
See More
Curis Closes $80.8 Million PIPE Financing to Advance Cancer Drug Development
- Successful Financing: Curis, Inc. has closed a PIPE financing of up to $80.8 million, with initial gross proceeds of approximately $20.2 million, significantly enhancing the company's financial capacity to advance the development of its cancer drug emavusertib.
- Investor Participation: The financing attracted participation from several healthcare-focused institutional investors, including Nantahala Capital and Stonepine Capital Management, reflecting strong market confidence in Curis's future growth prospects.
- Drug Development Progress: Emavusertib is currently undergoing clinical trials for relapsed/refractory primary central nervous system lymphoma, which is expected to provide new treatment options for patients and further solidify the company's position in the biotechnology sector.
- Strategic Collaboration: Curis's collaboration with Aurigene Discovery Technologies grants it exclusive rights to develop emavusertib, with plans to continue clinical research in areas such as acute myeloid leukemia, thereby expanding its therapeutic portfolio.
See More
Innovative Eyewear Inc Reports 45% Year-over-Year Sales Growth in Q4
- Significant Sales Growth: Innovative Eyewear Inc (LUCY) reported preliminary Q4 sales of approximately $1 million, reflecting a 45% year-over-year increase, indicating enhanced competitiveness in the market that may attract more investor interest.
- Stock Surge: Following the sales report, LUCY's stock price surged 47% to $1.74, reflecting strong market confidence in the company's future growth potential, which could further enhance its financing capabilities.
- Industry Dynamics: The ISM services PMI rose for the third consecutive month to a reading of 54.4 in December, exceeding market expectations of 52.3, indicating signs of economic recovery that may positively influence overall market sentiment.
- Labor Market Changes: U.S. job openings fell by 303,000 to 7.146 million in November, marking the lowest level since December 2020, suggesting potential pressures in the labor market that could impact future economic growth expectations.
See More
UniFirst Corp Reports Mixed Q1 Results, Shares Drop 4%
- Earnings Miss: UniFirst Corp reported adjusted earnings of $1.97 per share for Q1, falling short of market expectations of $2.06, indicating challenges in profitability that may affect investor confidence.
- Sales Slightly Exceed Expectations: The company’s quarterly sales reached $621.318 million, slightly above the expected $615.253 million, suggesting some market demand remains despite earnings concerns.
- Stock Price Reaction: Following the mixed results, UniFirst's shares dropped approximately 4% on Wednesday, reflecting market worries about the company's future profitability and potentially prompting investors to reassess their strategies.
- Industry Impact: In a mixed market where healthcare stocks rose by 1.4% and materials stocks fell by 1%, UniFirst's performance may influence its competitive position within the materials sector.
See More
Curis Secures $80.8 Million PIPE Financing to Support R&D Efforts
- Financing Size: Curis, Inc. has entered into a securities purchase agreement for a PIPE financing of up to $80.8 million, with initial gross proceeds of approximately $20.2 million expected to close on January 8, 2026, significantly enhancing the company's liquidity to support R&D.
- Equity Structure: The financing includes 20,195 shares of Series B convertible preferred stock and various warrants, which are expected to provide additional capital to advance the company's drug development in acute myeloid leukemia and other cancers.
- Strategic Use: Curis intends to utilize the initial net proceeds for research and development, general corporate expenses, and working capital needs, ensuring the company maintains a competitive edge in the biotechnology sector.
- Market Reaction: The successful completion of this financing is expected to accelerate the clinical trial process for emavusertib, enhancing market confidence in its products, which could positively impact the company's future stock price.
See More
Curis Secures $80.8 Million in PIPE Financing
- Financing Size: Curis, Inc. announced a securities purchase agreement for a PIPE financing expected to yield up to $80.8 million, with initial gross proceeds of approximately $20.2 million, highlighting the company's appeal in the biotechnology sector.
- Investor Composition: The financing attracted several high-quality healthcare institutional investors and company insiders, indicating strong market confidence and support for Curis, which may enhance the company's funding strength for future R&D.
- Use of Funds: Curis intends to utilize the initial net proceeds for research and development, general corporate expenses, and working capital needs, ensuring its sustained growth in the competitive biopharmaceutical market.
- Shareholder Approval: The issuance of Series B Preferred Stock and Warrants requires shareholder approval, and the successful completion of this process will lay the groundwork for optimizing the company's future capital structure.
See More
